S.C. Ropharma S.A.

BVB:RPH Stock Report

Market Cap: RON 103.3m

S.C. Ropharma Management

Management criteria checks 2/4

S.C. Ropharma's CEO is Mihai Miron, appointed in Jan 2009, has a tenure of 17.5 years. directly owns 20.51% of the company’s shares, worth RON21.19M. The average tenure of the management team and the board of directors is 16.5 years and 19.5 years respectively.

Key information

Mihai Miron

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure17.5yrs
CEO ownership20.5%
Management average tenure16.5yrs
Board average tenure19.5yrs

Recent management updates

Recent updates

Analysis Article • Dec 06

S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
Analysis Article • Dec 09

Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article • Sep 23

S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article • Jun 01

Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Mar 16

Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Analysis Article • May 15

S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Mar 26

S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article • Dec 23

Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Analysis Article • Nov 24

We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...

CEO

Mihai Miron (66 yo)

17.5yrs
Tenure

Dr. Pharmacist. Mihai Miron serves as Chairman since 2009 and Chief Executive Officer of Ropharma SA.

Leadership Team

NamePositionTenureCompensationOwnership
Mihai Miron
Chairman17.5yrsno data20.51%
RON 21.2m
Alin Radasanu
CFO & Member of the Board of Directors16.5yrsno datano data
Danut Ene
HR Director & Member of Board of Directors14.5yrsno datano data
16.5yrs
Average Tenure
58yo
Average Age

Experienced Management: RPH's management team is seasoned and experienced (16.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mihai Miron
Chairman17.5yrsno data20.51%
RON 21.2m
Alin Radasanu
CFO & Member of the Board of Directors19.5yrsno datano data
Danut Ene
HR Director & Member of Board of Directors19.5yrsno datano data
Florentina Miron
Member of the Board of Directors19.5yrsno data1.38%
RON 1.4m
Doru Vasile Darabus
Member of the Board of Directors17.5yrsno datano data
Mihai Bratescu
Member of the Board of Directors19.5yrsno data1.13%
RON 1.2m
Ovidiu Nut
Member of the Board of Directors10.3yrsno datano data
19.5yrs
Average Tenure
65yo
Average Age

Experienced Board: RPH's board of directors are seasoned and experienced ( 19.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 05:07
End of Day Share Price 2026/07/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

S.C. Ropharma S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.